Literature DB >> 21045154

Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models.

Erika R Amstalden van Hove1, Tiffany R Blackwell, Ivo Klinkert, Gert B Eijkel, Ron M A Heeren, Kristine Glunde.   

Abstract

Phosphocholine (PC) and total choline (tCho) are increased in malignant breast tumors. In this study, we combined magnetic resonance spectroscopic imaging (MRSI), mass spectrometry (MS) imaging, and pathologic assessment of corresponding tumor sections to investigate the localization of choline metabolites and cations in viable versus necrotic tumor regions in the nonmetastatic MCF-7 and the highly metastatic MDA-MB-231 breast cancer xenograft models. In vivo three-dimensional MRSI showed that high tCho levels, consisting of free choline (Cho), PC, and glycerophosphocholine (GPC), displayed a heterogeneous spatial distribution in the tumor. MS imaging performed on tumor sections detected the spatial distributions of individual PC, Cho, and GPC, as well as sodium (Na+) and potassium (K+), among many others. PC and Cho intensity were increased in viable compared with necrotic regions of MDA-MB-231 tumors, but relatively homogeneously distributed in MCF-7 tumors. Such behavior may be related to the role of PC and PC-related enzymes, such as choline kinase, choline transporters, and others, in malignant tumor growth. Na+ and K+ colocalized in the necrotic tumor areas of MDA-MB-231 tumors, whereas in MCF-7 tumors, Na+ was detected in necrotic and K+ in viable tumor regions. This may be attributed to differential Na+/K+ pump functions and K+ channel expressions. Principal component analysis of the MS imaging data clearly identified different tumor microenvironmental regions by their distinct molecular signatures. This molecular information allowed us to differentiate between distinct tumor regions and tumor types, which may, in the future, prove clinically useful in the pathologic assessment of breast cancers.
Copyright © 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045154      PMCID: PMC5555163          DOI: 10.1158/0008-5472.CAN-10-0360

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections.

Authors:  Pierre Chaurand; Sarah A Schwartz; Richard M Caprioli
Journal:  Curr Opin Chem Biol       Date:  2002-10       Impact factor: 8.822

Review 2.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 3.  Mass spectrometric imaging for biomedical tissue analysis.

Authors:  Kamila Chughtai; Ron M A Heeren
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Choline kinase alpha in cancer prognosis and treatment.

Authors:  Kristine Glunde; Zaver M Bhujwalla
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

5.  Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline.

Authors:  Noriko Mori; Robert Delsite; Kshama Natarajan; Mariola Kulawiec; Zaver M Bhujwalla; Keshav K Singh
Journal:  Mol Imaging       Date:  2004-10       Impact factor: 4.488

6.  Choline transporter as a novel target for molecular imaging of cancer.

Authors:  Toshihiko Hara; Aditya Bansal; Timothy R DeGrado
Journal:  Mol Imaging       Date:  2006 Oct-Dec       Impact factor: 4.488

7.  (1)H spectroscopic imaging of human brain at 3 Tesla: comparison of fast three-dimensional magnetic resonance spectroscopic imaging techniques.

Authors:  Matthew L Zierhut; Esin Ozturk-Isik; Albert P Chen; Ilwoo Park; Daniel B Vigneron; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2009-09       Impact factor: 4.813

8.  Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.

Authors:  Ana Ramírez de Molina; Jacinto Sarmentero-Estrada; Cristóbal Belda-Iniesta; Miquel Tarón; Victor Ramírez de Molina; Paloma Cejas; Marcin Skrzypski; David Gallego-Ortega; Javier de Castro; Enrique Casado; Miguel Angel García-Cabezas; Jose Javier Sánchez; Manuel Nistal; Rafael Rosell; Manuel González-Barón; Juan Carlos Lacal
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

9.  Extracellular acidification alters lysosomal trafficking in human breast cancer cells.

Authors:  Kristine Glunde; Sandra E Guggino; Meiyappan Solaiyappan; Arvind P Pathak; Yoshitaka Ichikawa; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

10.  Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR.

Authors:  Cristina Gabellieri; Mounia Beloueche-Babari; Yann Jamin; Geoffrey S Payne; Martin O Leach; Thomas R Eykyn
Journal:  NMR Biomed       Date:  2009-05       Impact factor: 4.044

View more
  24 in total

1.  Lipid analysis of eight human breast cancer cell lines with ToF-SIMS.

Authors:  Michael A Robinson; Daniel J Graham; Fionnuala Morrish; David Hockenbery; Lara J Gamble
Journal:  Biointerphases       Date:  2015-06-28       Impact factor: 2.456

2.  Fiducial markers for combined 3-dimensional mass spectrometric and optical tissue imaging.

Authors:  Kamila Chughtai; Lu Jiang; Tiffany R Greenwood; Ivo Klinkert; Erika R Amstalden van Hove; Ron M A Heeren; Kristine Glunde
Journal:  Anal Chem       Date:  2012-02-07       Impact factor: 6.986

3.  Identification of Biomarkers of Necrosis in Xenografts Using Imaging Mass Spectrometry.

Authors:  Roberto Fernández; Jone Garate; Sergio Lage; Silvia Terés; Mónica Higuera; Joan Bestard-Escalas; Daniel H López; Francisca Guardiola-Serrano; Pablo V Escribá; Gwendolyn Barceló-Coblijn; José A Fernández
Journal:  J Am Soc Mass Spectrom       Date:  2015-09-25       Impact factor: 3.109

4.  Analysis of the lipidome of xenografts using MALDI-IMS and UHPLC-ESI-QTOF.

Authors:  Roberto Fernández; Sergio Lage; Beatriz Abad-García; Gwendolyn Barceló-Coblijn; Silvia Terés; Daniel H López; Francisca Guardiola-Serrano; M Laura Martín; Pablo V Escribá; José A Fernández
Journal:  J Am Soc Mass Spectrom       Date:  2014-04-24       Impact factor: 3.109

Review 5.  MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications.

Authors:  Benjamin Balluff; Cedrik Schöne; Heinz Höfler; Axel Walch
Journal:  Histochem Cell Biol       Date:  2011-07-30       Impact factor: 4.304

6.  MALDI-Mass Spectrometric Imaging Revealing Hypoxia-Driven Lipids and Proteins in a Breast Tumor Model.

Authors:  Lu Jiang; Kamila Chughtai; Samuel O Purvine; Zaver M Bhujwalla; Venu Raman; Ljiljana Paša-Tolić; Ron M A Heeren; Kristine Glunde
Journal:  Anal Chem       Date:  2015-06-04       Impact factor: 6.986

Review 7.  Choline metabolism-based molecular diagnosis of cancer: an update.

Authors:  Kristine Glunde; Marie-France Penet; Lu Jiang; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Expert Rev Mol Diagn       Date:  2015-04-28       Impact factor: 5.225

8.  Discovering New Lipidomic Features Using Cell Type Specific Fluorophore Expression to Provide Spatial and Biological Specificity in a Multimodal Workflow with MALDI Imaging Mass Spectrometry.

Authors:  Marissa A Jones; Sung Hoon Cho; Nathan Heath Patterson; Raf Van de Plas; Jeffrey M Spraggins; Mark R Boothby; Richard M Caprioli
Journal:  Anal Chem       Date:  2020-05-06       Impact factor: 6.986

9.  Live-cell vibrational imaging of choline metabolites by stimulated Raman scattering coupled with isotope-based metabolic labeling.

Authors:  Fanghao Hu; Lu Wei; Chaogu Zheng; Yihui Shen; Wei Min
Journal:  Analyst       Date:  2014-05-21       Impact factor: 4.616

10.  Imaging the clear cell renal cell carcinoma proteome.

Authors:  Todd M Morgan; Erin H Seeley; Oluwole Fadare; Richard M Caprioli; Peter E Clark
Journal:  J Urol       Date:  2012-09-23       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.